Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

NEWRON PHARMACEUTICALS SPA

(NWRN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/12/2019 03/13/2019 03/14/2019 03/15/2019 03/18/2019 Date
8.53(c) 8.29(c) 8.18(c) 8.2(c) 8.01 Last
11 116 56 727 28 590 5 089 8 520 Volume
-3.62% -2.81% -1.33% +0.24% -2.32% Change
More quotes
Financials (EUR)
Sales 2019 8,29 M
EBIT 2019 -24,6 M
Net income 2019 -23,8 M
Finance 2019 27,4 M
Yield 2019 -
Sales 2020 17,0 M
EBIT 2020 -23,9 M
Net income 2020 -15,4 M
Finance 2020 12,1 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 12,3x
EV / Sales2020 6,87x
Capitalization 129 M
More Financials
Company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company... 
Sector
Biotechnology & Medical Research
Calendar
04/02 | 05:00amShareholder meeting
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
03/05Newron announces 2018 financial results and provides outlook for 2019
TE
03/01NEWRON PHARMACEUTICALS : Supports Global Rare Disease Day 2019
AQ
02/28NEWRON PHARMACEUTICALS : Supports Global Rare Disease Day® 2019
BU
02/20NEWRON PHARMACEUTICALS : to Present at the 8th Annual SVB Leerink Global Healthc..
BU
02/04NEWRON PHARMACEUTICALS : Completes Patient Enrollment in Pivotal STARS Study
AQ
02/01NEWRON PHARMACEUTICALS : to Present at the 21st Annual BIO CEO and Investor Conf..
AQ
02/01Newron Completes Patient Enrollment in Pivotal STARS Study
TE
01/31NEWRON PHARMACEUTICALS : to Present at the 21st Annual BIO CEO & Investor Confer..
BU
01/17NEWRON PHARMACEUTICALS : - Commercialization partner Zambon together with Valeo ..
AQ
01/16NEWRON PHARMACEUTICALS : Commercialization Partner Zambon Together with Valeo Ph..
BU
More news
Analyst Recommendations on NEWRON PHARMACEUTICALS SPA
More recommendations
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 27,4 €
Spread / Average Target 279%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA46.17%146
GILEAD SCIENCES4.92%83 712
VERTEX PHARMACEUTICALS13.51%48 087
REGENERON PHARMACEUTICALS10.97%44 500
GENMAB5.15%10 483
SAREPTA THERAPEUTICS INC17.62%9 457